Evidence Based Hair

Season 3, Episode 2 (LPP, FFA, Checkpoint Inhibitor induced LPP, Scarring Alopecia ”Gene Signatures”, Alopecic and Aseptic Nodules of the Scalp)

Recording of the Evidence Based Hair Podcast for the Oct 17, 2022 issue. 
 
LICHEN PLANOPILARIS COMORBIDITY STUDIES
Conic et al (starts 8:19). Exploring the association between lichen planopilaris, cardiovascular and metabolic disorders. J Eur Acad Dermatol Venereol 2021 Nov;35(11):e826-e828.
Joshi et al (starts 9:59). Comorbidities associated with lichen planopilaris: a case-control study using the All of Us database. Int J Dermatol. 2022 Oct 2.
Nasimi et al (starts 15:45) Comorbidities in Patients with Lichen Planopilaris: A Case-Control Study. Skin Appendage Disord. 2022 Jul;8(4):302-306.
 
FRONTAL FIBROSING ALOPECIA STUDIES
Imhof RL et al (starts 20:21). Eyebrow hair loss as a prognostic factor for frontal fibrosing alopecia. JAAD Int. 2022 Aug 18;
Rosales Santillan M et al (starts 26:52). Exploring potential decreasing age of patients with frontal fibrosing alopecia. JAAD Int. 2022 Jul 22;
Doche et al (starts 35:52). "Normal-appearing" scalp areas are also affected in lichen planopilaris and frontal fibrosing alopecia: An observational histopathologic study of 40 patients. Exp Dermatol . 2020 Mar;29(3):278-281.
Porrino-Bustamante et al (starts 36:30). Frontal Fibrosing Alopecia: A Histopathological Comparison of the Frontal Hairline with Normal-Appearing Scalp. J Clin Med 2022; Jul 15;11(14):4121
 
CHECKPOINT INHIBITORS AND SCARRING ALOPECIA
Braasch et al (starts 45:25). Scarring Alopecia Under Immune Checkpoint Blockade: a Report of Three Cases. Acta Derm Venereol. 2022 Oct 11;102:adv00792.
 
GENE SIGNATURES IN PRIMARY SCARRING ALOPECIA
Wang EHC et al (starts 55:10). Primary cicatricial alopecias are characterized by dysregulation of shared gene expression pathways. PNAS Nexus . 2022 Jul 11;1(3):pgac111
 
ALOPECIC AND ASEPTIC NODULES OF THE SCALP (AANS):
Luu NHC et al (starts 1:06:42). Alopecic and Aseptic Nodules of the Scalp: A New Entity or a Minor Form of Dissecting Cellulitis? Int J Trichology. 2022 Jul-Aug;14(4):120-124

Season 3, Episode 1 (Isotretinoin, Trichotillomania, Blue Sclera, Omicron, Tinea Capitis from Guinea Pigs)

Recording of the Evidence Based Hair Podcast for the Oct 11, 2022 issue. 
TINEA CAPITIS STUDIES
Cukierman E et al (starts at 5:18). Alopecia and pet: a case report. Einstein (Sao Paulo). 2022 Jul 4;20:eRC6881.
 
TELOGEN EFFLUVIUM - COVID 19
Visconti A et al (starts at 20:00) Cutaneous Manifestations of SARS-CoV-2 infection during the Delta and Omicron waves in 348,691 UK users of the UK ZOE COVID Study App. Br J Dermatol. 2022 Jul 22;
 
TELOGEN EFFLUVIUM - ISOTRETINOIN
Tran PT et al (starts at 29:30) Characteristics of Patients with Hair Loss after Isotretinoin Treatment: A Retrospective Review Study. Int J Trichology. 2022 Jul-Aug;14(4):125-127.
 
TRICHOTILLOMANIA STUDIES
Grant JE and Chamberlain SR (starts at 42:17). Natural recovery in trichotillomania. Aust N Z J Psychiatry. 2022 Oct;56(10):1357-1362
 
Chesivoir EK et al (starts at 47:30). Comorbid trichotillomania and attention deficit hyperactivity disorder in adults. Psychiatry. 2022 Jul; TELOGEN EFFLUVIUM -
 
IRON DEFICIENCY
 
Kano Y. Blue sclera (starts at 55:33): An overlooked finding of iron deficiency. Cleve Clin J Med. 2022 Oct 3;89(10):549-550.
 
 

Season 2, Episode 10 (Oral minoxidil, Hair Fibers, HCQ in Pregnancy, Teriflunomide-induced Hair Loss, Do it Yourself Haircare, Premature Greying of Hair)

ORAL MINOXIDIL IN PEDIATRICS
 
Jerjen R et al (starts at 12:33). Low-dose oral minoxidil improves global hair density and length in children with loose anagen hair syndrome. Br J Dermatol. 2021;184(5):977-978.
Nicolas-Ruanes et al (starts at 15:33). Low-dose oral minoxidil for treatment of androgenetic alopecia and telogen effluvium in a pediatric population: A descriptive study. J Am Acad Dermatol. 2022 Apr 26;
John JM et al (starts at 17:24). Safety and tolerability of low-dose oral minoxidil in adolescents: A retrospective review. J Am Acad Dermatol . 2022 Jul 5;S0190-9622(22)02245-9.
 
HAIR FIBERS AND CAMOUFLAGE
Ring and Keller (starts at 25:13). Effect of camouflaging agents on psychologic well-being: A cross-sectional survey of hair loss patients. J Am Acad Dermatol. 2017 Jun;76(6):1186-1189
Babadjouni A et al (starts at 28:15). Patient Satisfaction and Adverse Effects Following the use of Topical Hair Fiber Fillers. Int J Trichology. 2022 May-Jun; 14(3): 97–102
 
HYDROXYCHLOROQUINE IN PREGNANCY
Reynolds JA et al (starts at 34:38). Outcomes of children born to mothers with systemic lupus erythematosus exposed to hydroxychloroquine or azathioprine. Rheumatology (Oxford). 2022 Jun 29:
Sperber K et al (starts at 38:25). Systematic review of hydroxychloroquine use in pregnant patients with autoimmune diseases. Pediatr Rheumatol Online J 2009;7:9.
Kaplan Y et al (starts at 39:17). Reproductive outcomes following hydroxychloroquine use for autoimmune diseases: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016 May;81(5):835-48.
Clowse MEB et al (starts at 40:27). Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med. 2022 Mar;9(1):e000651.
Huybrechts K et al (starts at 42:37). Hydroxychloroquine early in pregnancy and risk of birth defects. Am J Obstet Gynecol 2021 Mar;224(3):290.e1-290.e22
Huybrechts K et al (starts at 45:20). Hydroxychloroquine early in pregnancy and risk of birth defects: absence of evidence is not the same as evidence of absence. Am J Obstet Gynecol. 2021 May;224(5):549-550.
Bérard et al (starts at 46:58). Chloroquine and Hydroxychloroquine Use During Pregnancy and the Risk of Adverse Pregnancy Outcomes Using Real-World Evidence. Front Pharmacol. 2021 Aug 2;12:722511.
Howley et al (starts at 47:17). Maternal exposure to hydroxychloroquine and birth defects. Birth Defects Res. 2021 Oct 15;113(17):1245-1256.
Andersson et al (starts at 47:34). Fetal safety of chloroquine and hydroxychloroquine use during pregnancy: a nationwide cohort study. Rheumatology (Oxford). 2021 May 14;60(5):2317-2326.
 
TERIFLUNOMIDE INDUCED HAIR LOSS IN MULTIPLE SCLEROSIS
Travis LH et al (starts at 53:28). Real-World Observational Evaluation of Hair Thinning in Patients with Multiple Sclerosis Receiving Teriflunomide: Is It an Issue in Clinical Practice? Neurol Ther. 2018 Dec; 7(2): 341–347.
Porwal MH et al (starts at 55:41). Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies. J Cent Nerv Syst Dis. 2022 Jun 23;14:11795735221109674.
 
DO IT YOURSELF LOW-ALLERGEN PRODUCTS
Xiong M and Warshaw EM. (starts at 1:05:45) Hair Care Product Hacks: Do It Yourself Alternatives. Dermatitis. 2022 Jun 29.
Zirwas M and Moennich J (starts at 1:00:25). Shampoos. Dermatitis. 2009 Mar-Apr;20(2):106-10
Tawfik M, Rodriguez-Homs LG, Alexander T, et al (starts at 1:01:10). Allergen content of  best-selling ethnic versus nonethnic shampoos, conditioners, and styling products. Dermatitis 2021;32(2):101–110
https://donovanmedical.com/diy
 
PREMATURE GREYING (EARLY CANITIES)
Anggraini et al (starts at 1:08:50). Risk Factors Associated with Premature Hair Greying of Young Adult. Open Access Maced J Med Sci . 2019 Nov 14;7(22):3762-3764.
Dawber RP (starts at 1:09:12). Integumentary associations of pernicious anaemia. Br J Dermatol . 1970 Mar;82(3):221-3.
Mosley JG and Gibbs AC (starts at 1:09:50). Premature grey hair and hair loss among smokers: a new opportunity for health education? British Medical Journal 1996; 313: 1616.
Bhat RM et al (starts at 1:10:21). Epidemiological and investigative study of premature graying of hair in higher secondary and pre-university school children. Int J Trichology. 2013;5:17–21.
Chang H-C and Sung C-W (starts at 1:10:35). Association between serum levels of minerals and premature hair graying: a systematic review and meta-analysis. Int J Dermatol. 2020 Oct;59(10):e378-e380.
Schnohr P et al (starts at 1:12:35). Longevity and gray hair, baldness, facial wrinkles, and arcus senilis in 13,000 men and women: The Copenhagen city heart study. J Gerontol A Biol Sci Med Sci. 1998;53:M347–50.
Schnohr P et al. Gray hair, baldness, and wrinkles in relation to myocardial infarction: the Copenhagen City Heart Study. Am Heart J  1995 Nov;130(5):1003-10.
 
Kocaman SA et al (starts at 1:14:10) . The degree of premature hair graying as an independent risk marker for coronary artery disease: A predictor of biological age rather than chronological age. Anadolu Kardiyol Derg 2012;12:457-63. 
Paik S et al (starts at 1:14:25). Association Between Premature Hair Greying and Metabolic Risk Factors: A Cross-sectional Study. Acta Derm Venereo. 2018 Aug 29;98(8):748-752.
Mahendiratta S et al (starts at 1:15:09). Premature graying of hair: Risk factors, co-morbid conditions, pharmacotherapy and reversal-A systematic review and meta-analysis. Dermatol Ther. 2020 Nov;33(6):e13990.
Das S et al (starts at 1:15:51) Cardiovascular risk markers in premature canities. Indian J Dermatol Venereol Leprol. 2022 Jun 30;1-5.

Season 2, Episode 9 (Isotretinoin and Finasteride for FFA, Eyelash Loss in FFA, Male FFA, LPP Incidence and Prevalence, CCCA Quality of Life)

FRONTAL FIBROSING ALOPECIA :
ISOTRETINOIN VS FINASTERIDE
Rakowska A, et al (starts at 9:15). Efficacy of Isotretinoin and Acitretin in Treatment of Frontal Fibrosing Alopecia: Retrospective Analysis of 54 Cases. J Drugs Dermatol. 2017.
Rokni GR et al (starts at 10:43). Evaluating the combined efficacy of oral isotretinoin and topical tacrolimus versus oral finasteride and topical tacrolimus in frontal fibrosing alopecia - A randomized controlled trial. J Cosmet Dermatol. 2022 Jul 11.
 
FRONTAL FIBROSING ALOPECIA : EYELASH INVOLVEMENT
Salas-Callo C et al (starts at 16:14). Eyelash involvement in frontal fibrosing alopecia: A prospective study. J Am Acad Dermatol 2022 Jul;87(1):232-234.
 
FRONTAL FIBROSING ALOPECIA : QUALITY OF LIFE
David Saceda-Corralo et al (starts at 22:52). Health-Related Quality of Life in Patients With Frontal Fibrosing Alopecia. JAMA Dermatol. 2018 Apr 1;154(4):479-480.
Varghae A et al (starts at 24:43). Assessment of health-related quality of life in patients with frontal fibrosing alopecia. J Cosmet Dermatol. 2022 Jun 27.
 
FRONTAL FIBROSING ALOPECIA : MALE FFA STUDIES OF ORAL MINOXIDIL AND FINASTERIDE/DUTASTERIDE
Moussa A et al (starts at 30:00). Clinical features and treatment outcomes of frontal fibrosing alopecia in men. Int J Dermatol. 2022 Jun 21
LPP PREVALENCE STUDIES
Trager MH et al (starts at 40:50). Prevalence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system. J Am Acad Dermatol 2021 Apr;84(4):1166-1169
Lavian J et al (starts at 41:37). Incidence estimates for lichen planopilaris and frontal fibrosing alopecia in a New York City health care system.Dermatol Online J. 2021 Aug 15;27(8).
Lim S H et al (starts at 42:29). Rapidly increasing incidence and prevalence of lichen planopilaris in an Asian population: A Korean nationwide population-based study. J Dermatol. 2022 Jun 21.
Joshi TP et al (starts at 49:10). Prevalence of lichen planopilaris in the United States: A cross-sectional study of the All of Us research program. JAAD Int. 2022 Jun 13;8:69-70
 
CENTRAL CENTRIFUGAL CICATRICIAL ALOPECIA: QUALITY OF LIFE
Akintilo et al (starts at 54:48). Health care barriers and quality of life in central centrifugal cicatricial alopecia patients. Cutis. 2018 Dec;102(6):427-432.
 
Maranga et al (starts at 56:49). Quality of life in patients with central centrifugal cicatricial alopecia: a preliminary study. Br J Dermatol. 2022 Jun 15.
 
 
CONCLUSION AND SUMMARY - starts at 58:46

Season 2, Episode 8 (COVID shedding, Trichotillomania, Traction Alopecia, Tinea Capitis Carrier State)

STUDIES REFERENCED
 
COVID RELATED SHEDDING
 
Mazeto IFS et al (starts at 6:09). Ultrastructural evidence for anagen hair follicle infection with SARS-CoV-2 in early-onset COVID-19 effluvium. J Eur Acad Dermatol Venereol. 2022 Jun 20.
 
Czech T et al (starts at 14:30). Characteristics of Hair Loss after COVID-19: Systematic Scoping Review. J Cosmet Dermatol. 2022 Jul 8.
 
 
TRICTHOTILLOMANIA
 
Thomson H et al (starts at 24:58). Prevalence and gender distribution of trichotillomania: A systematic review and meta-analysis. J Psychiatr Res. 2022 Jul 1;153:73-81.
 
TINEA CAPITIS  
 
Lecerf P et al (starts at 30:10). Asymptomatic Scalp Carriage among Household Contacts of Children Affected by Tinea Capitis: A Prospective Study in the Metropolitan Area of Brussels, Belgium.  Skin Appendage Disord. 2022 May;8(3):200-205.
 
TRACTION ALOPECIA
 
Lucia GS et al (starts at 42:30). Traction alopecia: Neglected in women and children of color. J Am Acad Dermatol. 2022 May 28;
 
FINAL COMMENTS AND SUMMARY - starts at 49:03

Season 2, Episode 7 (AGA and Smoking, Alopecia Areata and Eye Diseases, MTX for Pediatric AA, Upadacitinib for AA)

Kavadya T and Mysore V (starts at 5:24). Role of Smoking in Androgenetic Alopecia: A Systematic Review. Int J Trichology. 2022 Mar-Apr; 14(2): 41–48.
 
Mosley JG and Gibbs AC (starts at 6;30). Premature grey hair and hair loss among smokers: a new opportunity for heatlh education? British Medical Journal 1996; 313: 1616.
 
Su LH and Chen T H-H (starts at 7:38) Association of Androgenetic Alopecia with Smoking and Its Prevalence Among Asian Men. Archives of Dermatology 2007 143; 1401-1406.
 
 
 
Calvao J et al (starts at 9:16). Finasteride and Floppy Iris Syndrome: What Role Can the Dermatologist Play? Int J Trichology. May-Jun 2022;14(3):115-116.
 
Ting H-C et al (starts at 14:04). Association between alopecia areata and retinal diseases: A nationwide population-based cohort study. J Am Acad Dermatol . 2021 Nov 1;S0190-9622(21)02735-3.
 
Thatiparthi A et al (starts at 15:56). Inflammatory ocular comorbidities in alopecia areata: a retrospective cohort study of a single academic center. J Am Acad Dermatol. 2022 Jun 16;S0190-9622(22)01009-X
 
 
Albela H et al (starts at 19:32). Efficacy and Tolerability of Methotrexate in the Treatment of Severe Paediatric Alopecia Areata. Skin Appendage Disord. 2022 May;8(3):206-210.
 
 
Barton V et al (starts at 24:20). Treatment of pediatric alopecia areata: A systematic review. J Am Acad Dermatol. 2022 Jun;86(6):1318-1334.
 
 
Gambardella A, et al (starts at 29:18). Dual Efficacy of Upadacitinib in 2 Patients With Concomitant Severe Atopic Dermatitis and Alopecia Areata. Dermatitis 2021; 32: e85–e86.
 
Cantelli M et al (starts at 31:35). Upadacitinib improved alopecia areata in a patient with atopic dermatitis: a case report. Dermatol Ther. 2022; 1: e15346 
 
Asfour et al (starts at 32:35). Concurrent chronic alopecia areata and severe atopic dermatitis successfully treated with upadacitinib.  Int J Dermatol. 2022 Jun 20.
 
Gori N et al (starts at 33:53). Assessment of alopecia areata universalis successfully treated with upadacitinib. Int J Dermatol. 2022 Jul 2.
 
 
Conclusions and Summary (starts at 37:24)

Season 2, Episode 6 (JAK Inhibitors & Skin Cancer, Isotretinoin Labs, Triangular Alopecia, Hydroxychloroquine Retinopathy)

JAK KINASE INHIBITORS AND SKIN CANCER
Jalles et al (starts at 5:29). Skin cancers under Janus kinase inhibitors: A World Health Organization drug safety database analysis. Therapie. 2022 May 7;S0040-5957(22)00092-0.
 
ISOTRETINOIN LAB MONITORING
Xia E et al (starts at 13:36). Isotretinoin Laboratory Monitoring in Acne Treatment: A Delphi Consensus Study. JAMA Dermatol. 2022 Jun 15.
 
ISOTRETINOIN & SURGERY
Davis and Perkins (starts at 18:28). Oral isotretinoin (Roaccutane) use during incisional surgery: safe or risky? Case Reports Plast Surg Hand Surg. 2022 May 13;9(1):131-134.
Spring L et al (starts at 20:17). Isotretinoin and Timing of Procedural Interventions: A Systematic Review With Consensus Recommendations. JAMA Dermatol. 2017 Aug 1;153(8):802-809.
Mysore V et al. Standard Guidelines of Care: Performing Procedures in Patients on or Recently Administered with Isotretinoin J Cutan Aesthet Surg. 2017 Oct-Dec; 10(4): 186–194.
 
CONGENITAL TRIANGULAR ALOPECIA
Shimrada K et al (starts at 23:57). Atypical Localization of Congenital Triangular Alopecia Associated with Down's Syndrome. Indian J Dermatol. 2022 Jan-Feb; 67(1): 94
Starace M et al (starts at 25:40). Atypical Presentation of Congenital Triangular Alopecia: A Case Series in Italy. Dermatol Pract Concept Oct 2020.
 
HYDROXYCHLOROQUINE DOSING
Chen R et al (ssarts at 30:00). Impact of an Electronic Decision Support Tool to Improve Ophthalmic Safety in Hydroxychloroquine Prescribing Practices Ophthalmic Surg Lasers Imaging Retina. 2022 Jun;53(6):310-316.
Melles & Marmor (starts at 31:24). The Risk of Toxic Retinopathy in Patients on Long-term Hydroxychloroquine Therapy. JAMA Ophthalmol. 2014;132(12):1453–1460.

Season 2, Episode 5 (NAC for LPP, Hydroxychloroquine Melanosis, Linear Scleroderma, Dissecting Cellulitis in Women)

The third Monday of the month is dedicated to studies in scarring alopecia.
 
LICHEN PLANOPILARIS
 
Kahjoogh et al (starts at 5:34). Efficacy, safety, tolerability and satisfaction of N-acetylcysteine and pentoxifylline in lichen planopilaris patients under treatment with topical clobetasol: a triple arm blinded randomized controlled trial. Dermatol Ther. 2022 Jun 15
 
HYDROXYCHLOROQUINE
Beatriz Samões et al (starts at 24:05). Hydroxychloroquine induced melanosis. Reumatol Clin (Engl Ed). Jun-Jul 2022;18(6):377-378.
 
 
LINEAR SCLERODERMA
de Marsillac P et al (starts at 27:53). Clinical, epidemiological, trichoscopic and histopathological features of linear morphea on the scalp. J Eur Acad Dermatol Venereol. 2022 Jun 13. doi: 10.1111/jdv.18323. Online ahead of print
 
Ulc E et al (starts at 40:40). Therapeutic and Reconstructive Management Options in Scleroderma (Morphea) en Coup de Sabre in Children and Adults. A Systematic Literature Review. J Clin Med.
 
 
DISSECTING CELLULITIS
 
Melo DF et al (starts at 42:41). Dissecting cellulitis in women: a retrospective multicenter study with 17 patients. Int J Dermatol. 2022 May 15. doi: 10.1111/ijd.16271. Online ahead of print. May;86(5):e207-e208.
Ward N et al (starts at 48:03). Dissecting cellulitis of the scalp associated with peripheral and axial spondyloarthritis: report of a case and review of the literature. Clin Rheumatol 2022 Apr 23.

Season 2, Episode 4 (SSRI’s, COVID 19, iron, traction, trichotillomania)

DYSTROPHIC ANAGEN EFFLUVIUM IN COVID 19 SHEDDING
Shanshal M (start 7:52). COVID-19 related anagen effluvium. J Dermatolog Treat. 2022 Mar;33(2):1114-1115.
Anna Carolina Miola et al (starts 9:45). Early-onset effluvium secondary to COVID-19: Clinical and histologic characterization. J Am Acad Dermatol. 2022
 
ALTERNATE DAY IRON DOSING
Lale Aydın Kaynar et al (starts 12:57). Comparison of daily oral iron replacement therapy with every other day treatment in female reproductive age patients with iron-deficiency anemia. Ann Hematol. 2022 Apr 23.
Stoffel NU et al (starts 17:23). Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol. 2017 Nov;4(11):e524-e533.
Mehta S et al (starts 19:03). A Prospective, Randomized, Interventional Study of Oral Iron Supplementation Comparing Daily Dose with Alternate Day Regimen Using Hepcidin as a Biomarker in Iron Deficiency Anemia. J Assoc Physicians India. 2020 May;68(5):39-41.
 
INTRAVENOUS IRON
Aratsu et al (starts 22:57). Analysis of Adverse Events and Intravenous Iron Infusion Formulations in Adults With and Without Prior Infusion Reactions. JAMA Netw Open. 2022 Mar; 5(3): e224488.
 
SSRI AND HAIR LOSS
Etiman M et al (starts 29:44). Risk of hair loss with different antidepressants: a comparative retrospective cohort study. Int Clin Psychopharmacol 2018 Jan;33(1):44-48.
Pejcic and Paudel (starts 31:17). Alopecia associated with the use of selective serotonin reuptake inhibitors: Systematic review. Psychiatry Res. 2022 May 10;313:114620. ;86(5):e207-e208.
 
TRACTION ALOPECIA
Beach RA (starts 35:56). Case series of oral minoxidil for androgenetic and traction alopecia: Tolerability & the five C's of oral therapy. Dermatol Ther. 2018 Nov;31(6):e12707.
Kim and Craiglow (starts 36:38). Treatment of traction alopecia with oral minoxidil. JAAD Case Rep. 2022 Apr 1;23:112-113.
 
N ACETYL CYSTEINE IN TRICHOTILLOMANIA
Grant JE et al (starts 44:20). Arch Gen Psychiatry 2009
Bloch MH et al (starts 46:05) N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):231-40.
Popova L and Mancuso J (starts 48:09). Dramatic Improvement of Trichotillomania with 6 Months of Treatment With N-Acetylcysteine. Glob Pediatr Health. 2022 Mar 14;9:2333794X221086576.

Season 2, Episode 3 (Oral minoxidil in males, dutasteride microneedling, sleep disturbances in AGA, endothelial dysfunction in alopecia areata, pediatric alopecia areata)

ANDROGENETIC ALOPECIA STUDIES
Sanabria et al (starts at 4:40). Prospective cardiovascular evaluation with 24-h Holter and 24-h ambulatory blood pressure monitoring in men using 5 mg oral minoxidil for androgenetic alopecia. J Am Acad Dermatol. 2022 May 18;
Klein E et al (starts at 13:40). Comparing combination low-dose oral minoxidil and topical minoxidil with oral minoxidil alone for the treatment of non-scarring alopecia; a retrospective chart review. J Cosmet Dermatol. 2022 Jun 1.
Cao L et al (starts at 21:19). Nailfold capillaroscopy alterations in androgenetic alopecia: A cross-sectional study. Indian J Dermatol Venereol Leprol. 2022 Feb 28;1-7. doi: 10.25259/IJDVL_714_2021.
Emmanuel Sánchez-Meza et al (starts at 28:17). Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo-controlled study. J Eur Acad Dermatol Venereol. 2022 Jun 1. doi: 10.1111/jdv.18285. 
David Saceda-Corralo et al. Mesotherapy with Dutasteride in the Treatment of Androgenetic Alopecia. Int J Trichology. 2017 Jul-Sep; 9(3): 143–145.
Liamsombut S et al (starts at 34:45). Sleep quality in men with androgenetic alopecia. Sleep and Breathing. 2022 Apr 25.
 
 
ALOPECIA AREATA STUDIES
Anna Waśkiel-Burnat et al (starts at 41:33). Patients with alopecia areata are at risk of endothelial dysfunction: results of a case-control study. Clin Exp Dermatol. 2022 Mar 31.
Conic et al. Prevalence of cardiac and metabolic diseases among patients with alopecia areata.J Eur Acad Dermatol Venereol . 2021 Feb;35(2):e128-e129.
Youssef S et al (starts at 48:28). Tofacitinib Therapy for Alopecia Areata is not Associated with Adverse Events during COVID-19 Infection. J Am Acad Dermatol. 2022 May 9;S0190-9622(22)00795-2.
McKenzie P et al (starts at 53:32). Evaluation of the Prevalence and Incidence of Pediatric Alopecia Areata Using Electronic Health Record Data. JAMA Dermatol. 2022 May 1;158(5):547-551.